Advanced lipoprotein testing: recommendations based on current evidence.
Low-density lipoprotein cholesterol (LDL-C) level currently is used as the major determinant of lipid- and lipoprotein-associated risk for ischemic cardiovascular disease, and varying levels have become the standard goals of lipid-altering treatment. The predictive value of the LDL-C cholesterol level, however, often is less than that provided by other variables such as non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB), and the number of LDL particles measured by nuclear magnetic resonance spectroscopy. This article reviews studies that compare these different lipoprotein variables, describes advanced methodologies of lipoprotein testing, and suggests goals of treatment and clinical situations in which these tests might be ordered.
Lau
Joe F
JF
Mount Sinai Medical Center, Box 1030, 1 Gustave Levy Place, New York, NY 10029-6574, USA.
Smith
Donald A
DA
D000818:Animals; D001055:Apolipoproteins B / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood; D004586:Electrophoresis; D019317:Evidence-Based Medicine; D017408:Guidelines as Topic; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D009682:Magnetic Resonance Spectroscopy; D011237:Predictive Value of Tests; D014461:Ultracentrifugation
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008074:Lipoproteins